Mersana Therapeutics, Inc. (0M4.F)
- Previous Close
0.2546 - Open
0.2465 - Bid 0.2570 x --
- Ask 0.3659 x --
- Day's Range
0.2465 - 0.2465 - 52 Week Range
0.1809 - 2.5140 - Volume
200 - Avg. Volume
150 - Market Cap (intraday)
36.549M - Beta (5Y Monthly) 0.82
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5200 - Earnings Date Aug 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
www.mersana.comRecent News: 0M4.F
Más detallesPerformance Overview: 0M4.F
Trailing total returns as of 6/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Comparar con: 0M4.F
Puedes seleccionar hasta 4 acciones para analizar empresas similares utilizando métricas clave de rendimiento.
Statistics: 0M4.F
Más detallesValuation Measures
Market Cap
37.75M
Enterprise Value
-30.51M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.05
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-217.63%
Return on Assets (ttm)
-30.90%
Return on Equity (ttm)
--
Revenue (ttm)
34.01M
Net Income Avi to Common (ttm)
-74.01M
Diluted EPS (ttm)
-0.5200
Balance Sheet and Cash Flow
Total Cash (mrq)
102.29M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-36.67M